Categorie
Uncategorized

USA – How should CBO treat the “Most Favored Nation Model” interim final rule for Medicare Part B drugs? (Steven M. Lieberman, Brookings)

How should CBO treat the “Most Favored Nation Model” interim final rule for Medicare Part B drugs?